Case Study
From launch to thousands of purchases on Google and Meta
Building acquisition for a new GLP-1 telehealth brand in an increasingly competitive market.
When Four15 Digital began working with this telehealth startup in December 2022, its founder’s small Google campaign had produced just three patients. There was no mature acquisition program to scale. The work started with campaign structure, tracking, landing pages and a testing process across Google and Meta.
By the July 27, 2023 business review, Google reported 3,442 year-to-date purchases at $66.50 each. Meta reported 6,213 at $44.94 each. By the October 19 review, Stripe showed $320.5K in October-to-date net sales, up 32.5% against its displayed prior-month comparison.
|
Channel results reported in July QBR
|
Google
|
Meta
|
|---|---|---|
|
Year-to-date purchases
|
3,442
|
6,213
|
|
Year-to-date media sped
|
$228,912
|
$279,237
|
|
Reported cost per purchase
|
$66.50
|
$44.94
|
Each platform reports its own attributed purchases. The counts may overlap and should not be added as unique patients. The July QBR is dated July 27; its year-to-date results do not represent a completed July.
|
Stripe metric in October 19 notes
|
Prior-month comparison
|
October to date
|
|---|---|---|
|
Gross volume
|
$317.7K
|
$421.9K
|
|
Net volume from sales
|
$241.8K
|
$320.5K
|
|
Displayed net-sales growth
|
-
|
+32.5%
|
The revenue screenshots provide a business-level signal beyond ad-platform conversions. September’s review also showed net-sales growth against the comparison period. By October, both gross and net sales were growing by approximately one-third in the displayed month-to-date comparison.
These Stripe figures are rounded dashboard values and partial-month comparisons. Net sales are not net profit. They include business receipts beyond any single ad campaign, including possible recurring payments.
The initial review found limited historical Google activity and inadequate conversion tracking. Visitors left the site for Stripe checkout, and the homepage was the main available destination. Four15’s launch plan focused on high-intent search, measurable purchase activity and a separate creative and funnel-testing program for Facebook and Instagram.
We built medication-specific campaigns and helped replace a single homepage destination with relevant landing pages. Those pages went live on December 19, 2022. Search-term analysis informed keyword expansion and exclusions, while landing-page tests examined quiz starts, checkout activity and purchases together.
As purchase volume developed, we tested bidding toward purchases instead of relying on earlier checkout events. Some early tests did not improve results and were stopped. A later Mounjaro test showed a lower purchase CPA in the reviewed period and led to another test on Ozempic. We also concentrated work on the highest-value search themes, with more specific ads and destinations.
By July, the team had tested 163 ads. Simple creative with a clear medication-related message and a visible introductory offer became strong performers. The QBR’s leading ad reported 967 purchases at $23 per purchase; another reported 748 at $48. These were individual ad results, not account-wide acquisition costs.
We iterated on winning concepts, tested additional audience groups and adjusted spending as performance changed. Work continued through 2024 with campaign consolidation, new creative and product-specific campaigns. Both channels contributed meaningful acquisition volume, with Meta reporting the lower purchase cost in the July review.
We worked with the client on purchase tracking, duplicate-subscription issues, pricing tests and alternatives to the initial purchase flow. Landing-page and quiz tests were judged by purchases as well as earlier engagement. This mattered when a page generated more quiz activity without improving purchase conversion.
As the business grew, the focus expanded to retention and customer value. The notes document failed payments, refunds and differences in the economics of customer segments. By 2024, testing included commercial-insurance purchase events and separate compounded-medication campaigns, alongside continued work on Google and Meta.
Competitors were expanding, prices and offers were changing, and ad approvals repeatedly affected delivery. Four15 continued refining campaigns and funnels as the client changed its product and pricing. Experiments were not uniformly successful, and lower entry-price purchases did not automatically translate into stronger retention or profit.
The result was a substantial acquisition program built from an early starting point: thousands of reported purchases on each of the two core channels, supported by growing business receipts. The strongest evidence is the documented acquisition scale and Stripe sales growth; the supplied files do not establish a complete monthly revenue series or netprofit growth.